Tumor Necrosis Factor Inhibitor Drugs Market Size, Share, Trends, Value 2030

Tumor Necrosis Factor Inhibitor Drugs Market: Overview

According to the report, global demand for tumor necrosis factor inhibitor drugs market was valued at approximately USD 40.23 billion in 2018, and is expected to generate revenue of around USD 42.08 billion by end of 2025, growing at a CAGR of around 0.7% between 2019 and 2025.

Request Free Sample

The report covers forecasts and analyses for the tumor necrosis factor inhibitor drugs market on a global and regional level. The study provides historic data from 2016 along with forecasts from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the tumor necrosis factor inhibitor drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the tumor necrosis factor inhibitor drugs market on a global as well as regional level.

Tumor Necrosis Factor Inhibitor Drugs Market: Overview

In order to give the users of this report a comprehensive view on the tumor necrosis factor inhibitor drugs market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides a company market share analysis in order to give a broader overview of the key players in the tumor necrosis factor inhibitor drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the tumor necrosis factor inhibitor drugs market on a global and regional basis.

The study provides a crucial view of the tumor necrosis factor inhibitor drugs by segmenting the market based on product, application, distribution channel, and region. All the segments of the tumor necrosis factor inhibitor drugs market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.

Tumor necrosis factor (TNF) is a multifunctional protein cytokine produced by immune cells that causes inflammation in the body and plays important role in various cellular functions such as cell proliferation, differentiation, survival, and death. Tumor necrosis factor inhibitors suppress the body’s innate response to tumor necrosis factor (TNF). These inhibitors are used in the treatment of inflammatory conditions such as psoriatic arthritis, ulcerative colitis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, etc. These TNF inhibitor drugs are used in autoimmune disorders to avoid immune system attacks from healthy body cells.

Tumor Necrosis Factor Inhibitor Drugs Market: Report Scope

The demand for the tumor necrosis factor inhibitor drugs market is driven by increasing autoimmune disorders across the globe, increasing geriatric population base, promising pipelines, new product launches, increasing awareness among patients, increasing healthcare expenditure, and increasing disposable income. However, the emergence of new biosimilars as a result of loss of patent exclusivity in different regions, the internal threats from biosimilars, and intense competition from interleukin inhibitors are major factors that may hinder the market growth. Growing consumer preference for cost-effective therapeutics with improved efficacy and safety will bring new growth opportunities for market players over the forecast period.

Based on product, the global tumor necrosis factor inhibitor drugs market is bifurcated into Biosimilars, Cimzia, Simponi/Simponi Aria, Enbrel, Remicade, and Humira. The Humira product segment accounted for the largest market share in 2018 and is expected to retain its dominance over the forecast period. This is due to its patent exclusivity in the U.S. which will expire in 2023. The Biosimilar product segment will experience maximum growth over the forecast period as a result of patent expiry and new launches.

Based on applications market is segmented into psoriasis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, ankylosing spondylitis, and other applications. The rheumatoid arthritis application segment held dominating market share in 2018 driven by growing awareness, increasing incidence rate, and high treatment rate. Psoriatic arthritis and psoriasis application segments will witness the highest growth rate over the forecast period.

The distribution channel segment of the TNF inhibitor drugs market is divided into specialty pharmacies, hospital pharmacies and online pharmacies. The largest distribution channel in 2018 was hospital pharmacies. The online pharmacies distribution channel segment is projected to witness rapid growth in the coming years.

Tumor Necrosis Factor Inhibitor Drugs Market: Competitive Analysis

Major players in the tumor necrosis factor inhibitor drugs market are Merck & co., Inc., Pfizer, Inc., Novartis International AG, UCB S.A., Johnson & Johnson Services, Inc., Amgen Inc., and AbbVie Inc. among others.

Tumor Necrosis Factor Inhibitor Drugs Market: Regional Analysis

North America dominated the global tumor necrosis factor inhibitor drugs market in 2018. Strong commercial sales, favorable reimbursement policies, the presence of key players, a large patient pool, and growing awareness are major factors driving the growth in this region. Europe was the second largest regional market in terms of revenue share. Availability of developed infrastructure, increasing cases of autoimmune disorders, and growing awareness are some of the factors that boost the market growth in this region.

Request Free Sample

Asia Pacific region will be the rapidly growing market for tumor necrosis factor inhibitor drugs. Healthcare infrastructure improvement, economic development, increasing geriatric population base, increasing disposable income and healthcare spending, and growing awareness are important factors attributing to the rapid growth in this region. On the other hand, Latin America will experience moderate growth in the coming years. The Middle East and Africa will register slower growth in the years to come.

The report segment of global tumor necrosis factor inhibitor drugs market as follows:

Global Tumor Necrosis Factor Inhibitor Drugs Market: Product

• Humira
• Enbrel
• Remicade
• Simponi/Simponi Aria
• Cimzia
• Biosimilars

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Application

• Rheumatoid Arthritis
• Psoriasis
• Psoriatic Arthritis
• Crohn’s Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Hidradenitis Suppurativa
• Others

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of The Middle East & Africa